10591843/08a GAJJ: 1646
Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10591843	
	Filing Date		2006-09-05	
INFORMATION DISCLOSURE	First Named Inventor Tomo		oaki Hoshino et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission under 57 Of K 1.55)	Examiner Name	J.	Seharaseyon	
	Attorney Docket Numb	er	KUP-12	
			·	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document				Lines where ges or Relev	
	1										
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Name of Patentee of Applicant Releva				ages,Columns,Lines where elevant Passages or Relevant gures Appear		
	1										
If you wisl	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	button	Add		
				FOREIC	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e Or	vhere Rele	or Relevant	Т5
	1	2001510997	JP			2001-08-07	Karobio, A. et al.				
	2	63230637	JP			1988-09-27	Nikken Chemical C	o. Ltd.			
	3	0237189	EP			1987-09-16	Pigiet, V. et al.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10591843	10591843 - GAU: 1646
Filing Date		2006-09-05	
First Named Inventor	Tomo	aki Hoshino et al.	
Art Unit			
Examiner Name	J.	Seharasey	on
Attorney Docket Numb	er	KUP-12	

If you wis	h to ac	dd additional Foreign Pa		ation information plo LITERATURE DO	ease click the Add button	Add Remove	
	13	11147873	JP	1999-06-02	Hideki, A. et al.	Add	
	12	11100400	JP	1999-04-13	Kakuji, T. et al.		
	11	9724339	wo	1997-07-10	Kazuyuki, O. et al.		
	10	10504285	JP	1998-04-28	Bemis, G. W. et al.		
	9	5255218	JP	1993-10-05	Chapman, K. et al		
	8	5139992	JP	1993-06-08	Hiromi, W. et al.		
	7	11147895	JP	1999-06-02	Hideki, A. et al.		
	6	1085097	JP	1989-03-30	Jiyunji, Y. et al.		
	5	9832863	wo	1998-07-30	Spyrou, G.		
	4	2005060408	JP	2005-03-10	Jiyunji, Y. et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10591843	10591843 - GAU: 1646
Filing Date		2006-09-05	
First Named Inventor	Tomo	aki Hoshino et	al.
Art Unit			
Examiner Name	J	. Sehara	seyon
Attorney Docket Number		KUP-12	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T 5
	1	Ueda, S. et al., Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c1; J. Immunol, 1998 Vol. 161, No. 12 pp. 6689-6695.	
	2	Farina, A.R. et al; Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion; Eur. J. Biochem 26A, 405-413; (2001).	
	3	Sen, C.K.; Redox signaling and the emerging therapeutic potential of thiol and antioxidants; Biochem Pharmacol, 1998; Vol. 55, No. 11, pp 747-1758.	
	4	MacNee, W. et al.; Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease; Am. J. Respir. Crit Care Med; 1999; Vol. 160, No. 5, Pt 2; pp S58-65.	
	5	Pomerantz, J.J. et al.; Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta; Proc. Natl. Acad. Sci USA; 2001; Vol. 98, No. 5; P 2871-2876.	
	6	Pauwels, R.A. et al; "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBWHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary"; American Journal Respiratory Critical Care Medicine, vol.163:PP.1256-1276, 2001	
	7	Barnes, P.J. "Novel approaches and targets for treatment of chronic obstructive pulmonary disease"; American Journal Respiratory Critical Care Medicine; Vol.160: S72-79, 1999.	
	8	Shapiro, S.S.; "Animal models for COPD"; Chest, 117: 223S-227S, 2000	
	9	Perl, A. et al. "Early restriction of peripheral and proximal cell lineages during formation of the lung"; Proc Natl Acad Sci USA. 2002 Aug 6; 99 (16): 10482-10487	
	10	Stripp, B. et al.; "cis-acting elements that confer lung epithelial cell expression of the CC10 gene"; J Biol Chem. 1992 Jul 25; Vol. 267 (21): 14703-14712	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10591843	10591843 - GAU: 1646
Filing Date		2006-09-05	
First Named Inventor	Tomo	aki Hoshino et	al.
Art Unit			
Examiner Name		J. Sehar	aseyon
Attorney Docket Number		KUP-12	

11	Carroll, W.L. et al; "Hybridoma fusion cell lines contain an aberrant kappa transcript"; 1985. Mol. Immunol. Vol. 25 No. 19; 991-995	
12	Kozak, M.; "Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs"; Nucleic Acids Res. 1984 Jan 25; 12 (2): 857-72.	
13	Goldman, L.A. et al; "Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression"; Bio Techniques 21; 1013-1015; (1996).	
14	Hoshino T, et al; "Cuting edge: IL-18-transgenic mice: In Vivo evidence of a broad role for IL-18 in modulating immune function"; J Immunol 2001; 166: 7014-7018	
15	Kawase Y, et al; "Exacerbated and Prolonged Allergic and Non-Allergic Inflammatory Cutaneous Reaction in Mice with targeted Interleukin-18 Expression in the Skin"; J Invest Dermatol; 121; 502-509; (2003)	
16	Thornberry, N. et al.; "A Novel heterodimeric cysteine protease is required for interleukin 1b processing in monocytes" Nature 356; 768-775, 1992	
17	Novick, D. et al., "Interleukin-18 Binding Protein: A Novel Modulator of the Th1 Cytokine Response"; Immunity; Vol. 10; pp 127-136; 1999	
18	Kitasato, Y. et al.; "Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis"; AM J Respir Cell Mol Biol, 31: 619-625, 2004	
19	Palombella, V. et al.; "Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis"; Proc Natl Acad Sci USA. Vol. 95 PP. 15671-15676, December 1998 Medical Sciences	
20	Nakamura, H. et al.; "Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS; PNAS; Vol. 98, No. 5; 2688-2693 (2001)	
21	Reznikov, L. et al.; "The Combination of soluble IL-18Rα and IL-18Rβ Chains Inhibits IL-18-induced IFN-γ"; Journal of Interferon and cytokine research; 22: 593-601 (2002).	

	Application Number		10591843	10591843 - GAU: 164	
	Filing Date		2006-09-05		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Tomo	noaki Hoshino et al.		
	Art Unit				
(Not for Submission under or of R 1.33)	Examiner Name		J. Seharaseyon		
	Attorney Docket Numb	er	KUP-12		

	22		guchi, M. et al.; "Establishment of the cells useful for murine interle eukin-18 receptor cDNA into human myelomonocytic KG-1 cells";					
If you wisl	h to ac	ld add	ditional non-patent literature document citation information p	lease click the Add b	outton Add			
			EXAMINER SIGNATURE					
Examiner Signature /Jegathe		ture	/Jegatheesan Seharaseyon/	Date Considered	09/23/2010			
			reference considered, whether or not citation is in conforma rmance and not considered. Include copy of this form with r		_			
Standard ST ⁴ Kind of doo	Γ.3). ³ F cument	or Japa by the a	O Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office anese patent documents, the indication of the year of the reign of the Empe appropriate symbols as indicated on the document under WIPO Standard Son is attached.	eror must precede the ser	rial number of the patent doc	ument.		